MSCI Acquires Climate Risk Analytics Firm First Street
Money

MSCI Acquires Climate Risk Analytics Firm First Street

authorBy Natalie Pace
DateJun 25, 2026
Read Time2 min

MSCI's acquisition of First Street marks a significant step in bolstering its climate risk assessment offerings. This strategic integration is set to provide an enhanced platform for evaluating physical climate risks across various financial sectors, aiding in more informed capital allocation and risk management decisions.

MSCI Strengthens Climate Risk Portfolio with First Street Acquisition

In a pivotal development within the financial technology landscape, MSCI, a prominent U.S. financial services firm, has reached an agreement to acquire First Street, a leading provider of climate risk analytics. The deal, valued at an initial $120 million in cash, includes provisions for additional payments tied to First Street's future revenue performance over the subsequent two years. The transaction is slated for completion in the third quarter of 2026, pending regulatory approvals. Following the integration, First Street's sophisticated multi-hazard modeling capabilities and granular property-level analytics will be seamlessly incorporated into MSCI's comprehensive suite of climate and geospatial tools. This unified platform will empower clients to conduct precise physical climate risk assessments at virtually any global location, covering an extensive database of over two billion structures. Upon finalization, First Street's financial operations will merge into MSCI's Sustainability and Climate segment. Richard Mattison, Head of Sustainability and Climate at MSCI, emphasized that this integration will equip clients with superior insights into evolving risk exposures, directly translating into more strategic financial decision-making. Matthew Eby, founder and CEO of First Street, highlighted the acquisition's potential to embed property-level climate science into the daily operations of leading investors, lenders, and insurers, transforming climate risk considerations from mere disclosure exercises into fundamental inputs for capital pricing and allocation.

This acquisition underscores the increasing importance of climate risk in financial planning and investment strategies. It highlights a growing trend where financial institutions are proactively seeking advanced analytical tools to understand and mitigate the impacts of climate change on their portfolios. The enhanced capabilities resulting from this merger could set new industry standards for climate risk assessment, influencing how financial entities manage regulatory obligations, assess asset vulnerability, and ultimately, foster greater resilience in a changing global climate.

More Articles
Money
Elanco Animal Health: Poised for Significant Growth with New Blockbuster Products and Strategic Ventures
Elanco Animal Health (ELAN) is set for substantial long-term growth, driven by seven potential blockbuster product launches and the establishment of Elanco Ventures. Analysts project over 5% revenue expansion and approximately 10% EPS growth through 2032, supported by its strong market position and diversified portfolio in animal health.
By JL CollinsJun 25, 2026
Money
Prenetics Global Limited: A Bullish Outlook on Health and Longevity Market Expansion
Prenetics Global Limited (PRE) has garnered positive attention with a 'Buy' rating from Benchmark, citing the significant potential of its IM8 health and wellness brand. The company's recent financial results for Q1 2026 showcase strong growth, primarily driven by IM8, leading to an upward revision of its full-year revenue forecast for the brand. Prenetics is strategically positioning itself for sustained expansion through product diversification, market penetration, and leadership enhancements in the burgeoning nutritional supplements sector.
By Mr. Money MustacheJun 25, 2026
Money
Rocket Pharmaceuticals: A New Chapter After Key Gene Therapy Milestone
Rocket Pharmaceuticals has achieved a significant milestone with the restart of its RP-A501 dosing program and the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million. These developments have boosted the company's financial standing and extended its operational runway, positioning it for potential recovery and commercialization in the gene therapy space for rare pediatric diseases.
By Bola SokunbiJun 25, 2026
Money
Rare Buying Opportunity: Republic Services for Passive Income Investors
Republic Services (RSG) is experiencing a rare buying opportunity for passive income investors after a 17% pullback. The company's non-disruptable business model, CPI-linked pricing, and consistent dividend growth make it an attractive long-term investment. With strong free cash flow and institutional confidence, RSG offers a stable income stream designed to compound over decades, making it ideal for investors seeking enduring value amidst market fluctuations.
By T. Harv EkerJun 25, 2026
Money
ResMed Inc.: A Leader in Sleep Health and Respiratory Care
ResMed Inc. (RMD), a prominent global medical device company, continues to solidify its position as a leader in sleep health and respiratory care. Analysts are optimistic about its long-term potential, citing expanding markets and strategic acquisitions. The company's recent acquisition of Noctrix Health, Inc. further diversifies its portfolio, introducing innovative treatments for Restless Legs Syndrome and enhancing its connected health ecosystem. ResMed's commitment to improving patient outcomes through technological advancements positions it for sustained growth in the healthcare sector.
By Bola SokunbiJun 25, 2026